APUS - Apimeds Pharmaceuticals US, Inc.

1.33
0.030   2.256%

Share volume: 11,792
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$1.30
0.03
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
39%
Profitability 35%
Dept financing 43%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
-14.74%
3 Months
-37.56%
6 Months
-36.24%
1 Year
-39.55%
2 Year
-39.55%
Key data
Stock price
$1.33
P/E Ratio 
0.00
DAY RANGE
$1.30 - $1.35
EPS 
-$0.19
52 WEEK RANGE
$0.95 - $4.03
52 WEEK CHANGE
-$39.55
MARKET CAP 
22.385 M
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$26,436
AVERAGE 30 VOLUME 
$234,811
Company detail
CEO: Erik C. Emerson
Region: US
Website: www.apimedsus.com
Employees: 2
IPO year: 2025
Issue type:
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

We are a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects. We are located at 2 East Broad Street, 2nd Floor, Hopewell, New Jersey.

Recent news